Incyte | INCY - Pre Tax Profit


Incyte reported $751.51M in Pre-Tax Profit for its fiscal quarter ending in June of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
Agenus USD 39.21M 49.82M Mar/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Amgen USD 2.08B 570M Mar/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Biogen USD 647.3M 269.6M Jun/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
Exelixis USD 262.68M 5.01M Jun/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
Incyte USD 751.51M 407.91M Jun/2026
Ionis Pharmaceuticals USD -114M 21M Jun/2026
MacroGenics USD -36.77M 21.84M Mar/2026
Merck USD -3.53B 6.95B Mar/2026
Moderna USD -1.33B 535M Mar/2026
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 4.27B 430M Jun/2026
Novartis USD 3.84B 1.33B Mar/2026
Pfizer USD -653M 5.84B Jun/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Vertex Pharmaceuticals USD 1.39B 138.9M Jun/2026